Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18826183 | FUSION PROTEINS FOR IMMUNOTHERAPY AGAINST CANCER AND INFECTIOUS DISEASES | September 2024 | June 2025 | Allow | 9 | 1 | 0 | No | No |
| 18807087 | DIMERIC ANTIBODIES | August 2024 | May 2025 | Allow | 9 | 2 | 0 | No | No |
| 18640982 | COMPOSITIONS TARGETING BCMA AND METHODS OF USE THEREOF | April 2024 | December 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18588587 | USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF INFLAMMATORY CONDITIONS | February 2024 | October 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18429758 | CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASES | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18407065 | ANTI-L1CAM ANTIBODIES AND USES THEREOF | January 2024 | August 2025 | Allow | 19 | 2 | 0 | No | No |
| 18517345 | Use of Combination of Anti-PD-1 Antibody and VEGFR Inhibitor in Preparation of Drug for Treating Cancers | November 2023 | May 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18492141 | IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS | October 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18473858 | METHODS OF TREATING UROTHELIAL CARCINOMA USING AN ANTI-PD-1 ANTIBODY | September 2023 | June 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18454286 | Anti-SIRP-Alpha Antibodies and Methods of Use Thereof | August 2023 | October 2024 | Allow | 14 | 1 | 0 | No | No |
| 18315686 | MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE | May 2023 | November 2023 | Allow | 6 | 1 | 0 | No | No |
| 17914257 | ANTI-CCR8 ANTIBODIES FOR TREATING CANCER | September 2022 | January 2026 | Allow | 40 | 1 | 0 | Yes | No |
| 17907126 | MONOCLONAL ANTIBODIES AGAINST THE HEMAGGLUTININ (HA) AND NEURAMINIDASE (NA) OF INFLUENZA H3N2 VIRUSES | September 2022 | September 2025 | Allow | 36 | 0 | 0 | No | No |
| 17907070 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST | September 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17801075 | FLAVIVIRUS CROSS NEUTRALIZING ANTIBODY AND PHARMACEUTICAL COMPOSITION | August 2022 | December 2025 | Allow | 40 | 1 | 0 | No | No |
| 17817271 | ANTI TRBC1 ANTIGEN BINDING DOMAINS | August 2022 | September 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17846933 | HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM | June 2022 | January 2026 | Allow | 43 | 1 | 0 | No | No |
| 17831197 | PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF | June 2022 | March 2026 | Allow | 45 | 2 | 0 | No | No |
| 17830324 | ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES | June 2022 | July 2023 | Allow | 14 | 1 | 0 | No | No |
| 17778660 | METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-TIGIT ANTIBODIES | May 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17728598 | ANTI-ADGRE2 ANTIBODIES AND USES THEREOF | April 2022 | September 2025 | Allow | 41 | 3 | 0 | No | Yes |
| 17726537 | RECOMBINANT ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | April 2022 | October 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17769383 | AMH-COMPETITIVE ANTAGONIST ANTIBODY | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17700624 | ANTI-RHO GTPASE CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF | March 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17690526 | MAGE-A4 PEPTIDE-MHC ANTIGEN BINDING PROTEINS | March 2022 | December 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17674129 | ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | February 2022 | September 2025 | Allow | 43 | 4 | 1 | Yes | No |
| 17630437 | ANTI-IL13 ANTIGEN BINDING PROTEINS | January 2022 | January 2026 | Allow | 48 | 0 | 1 | No | No |
| 17578174 | METHODS OF TREATING UROTHELIAL CARCINOMA USING AN ANTI-PD-1 ANTIBODY | January 2022 | May 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17647665 | Bispecific Epitope Binding Protein Comprising Anti-4-1BB Antibody and a PD-1 Protein or Fragments Thereof and Use Thereof | January 2022 | February 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17552369 | Antitumor Agent | December 2021 | October 2025 | Abandon | 46 | 4 | 0 | Yes | Yes |
| 17543033 | RECOMBINANT FUSION PROTEINS TARGETING CD47 AND CD24, PREPARATION AND USE THEREOF | December 2021 | September 2023 | Allow | 21 | 1 | 0 | No | No |
| 17454634 | Use of Combination of Anti-PD-1 Antibody and VEGFR Inhibitor in Preparation of Drug for Treating Cancers | November 2021 | August 2023 | Allow | 21 | 2 | 0 | No | No |
| 17497597 | PD1 AND/OR LAG3 BINDERS | October 2021 | February 2025 | Allow | 41 | 1 | 1 | No | No |
| 17484483 | Targeting SARS-CoV-2 Viral-immune Interaction for COVID-19 Therapy | September 2021 | August 2025 | Allow | 46 | 4 | 1 | Yes | No |
| 17484003 | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED FC REGION | September 2021 | June 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17477905 | USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF INFLAMMATORY CONDITIONS | September 2021 | June 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17412089 | Antigen Binding Proteins that Bind BCMA | August 2021 | January 2026 | Allow | 53 | 1 | 1 | Yes | No |
| 17416237 | BISPECIFIC PROTEIN | June 2021 | April 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17351354 | ACTIVIN A ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | June 2021 | July 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17350223 | MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES | June 2021 | August 2025 | Allow | 50 | 2 | 0 | No | No |
| 17343022 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | June 2021 | September 2024 | Allow | 39 | 3 | 1 | No | No |
| 17299212 | HUMANISED ANTI-IL17BR ANTIBODY | June 2021 | September 2024 | Allow | 40 | 1 | 0 | No | No |
| 17317138 | CHIMERIC ANTIGEN RECEPTORS FOR PHAGOCYTOSIS | May 2021 | October 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17292269 | METHODS AND COMPOSITIONS FOR DETERMINING THE COMPOSITION OF A TUMOR MICROENVIRONMENT | May 2021 | March 2026 | Abandon | 58 | 3 | 0 | No | No |
| 17290816 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | May 2021 | November 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17245794 | GENE SIGNATURES FOR MONITORING ACUTE REJECTION AND METHODS OF USING SAME | April 2021 | October 2023 | Allow | 30 | 3 | 0 | Yes | No |
| 17231309 | IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS | April 2021 | July 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17285511 | TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMA | April 2021 | January 2025 | Allow | 45 | 4 | 0 | Yes | No |
| 17277396 | PROTEIN L FOR ACTIVATION AND EXPANSION OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED IMMUNE CELLS | March 2021 | September 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17181066 | Lyophilized Preparation | February 2021 | August 2024 | Allow | 42 | 2 | 0 | No | No |
| 17164834 | Universal T Cells and the Method of Use Thereof | February 2021 | February 2025 | Allow | 48 | 3 | 1 | No | No |
| 17259677 | ANTI-MESOTHELIN ANTIBODIES | January 2021 | January 2025 | Allow | 49 | 4 | 1 | Yes | No |
| 17259243 | EPITOPE SPECIFIC TO SMO PROTEIN, ANTIBODY RECOGNIZING SAME, AND COMPOSITION COMPRISING SAME | January 2021 | May 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17257820 | TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES | January 2021 | June 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17250286 | ANTI-L1CAM ANTIBODIES AND USES THEREOF | December 2020 | September 2023 | Allow | 32 | 1 | 0 | No | No |
| 17124971 | CD123 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY | December 2020 | October 2023 | Allow | 34 | 1 | 0 | No | No |
| 17251718 | PHARMACEUTICAL COMBINATIONS | December 2020 | May 2024 | Allow | 41 | 2 | 0 | No | No |
| 15734775 | ANTIBODY COMPLEX AND USES THEREOF | December 2020 | January 2025 | Allow | 50 | 2 | 0 | No | No |
| 17059961 | DOSING OF A BISPECIFIC ANTIBODY THAT BIND CD123 AND CD3 | November 2020 | November 2024 | Abandon | 48 | 0 | 1 | No | No |
| 17056301 | ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF | November 2020 | July 2024 | Allow | 44 | 1 | 0 | No | No |
| 17054496 | SUBSETS OF HUMAN NATURAL KILLER CELLS WITH ENHANCED ANTIBODY-DIRECTED IMMUNE RESPONSES | November 2020 | February 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17051987 | ANTIBODIES, AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND HER2 AND/OR APLP2, CONJUGATES, AND USES THEREOF | October 2020 | March 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17084783 | ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND GAMMA DELTA T-CELLS | October 2020 | March 2026 | Allow | 60 | 6 | 0 | Yes | Yes |
| 17051630 | MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO LAG-3 AND USE THEREOF | October 2020 | December 2023 | Allow | 37 | 2 | 0 | No | No |
| 17048106 | FUSION PROTEIN OF INTERFERON (IFN) AND ANTI-PD-L1 ANTIBODY AND USE THEREOF | October 2020 | April 2024 | Allow | 42 | 1 | 1 | No | No |
| 17041280 | METHODS AND COMPOSITIONS FOR BLOCKING INTERACTION BETWEEN NON-GLYCOSYLATED PD-1 POLYPEPTIDES | September 2020 | September 2024 | Abandon | 48 | 0 | 1 | No | No |
| 17030251 | C-TERMINALLY FUSED TNF FAMILY LIGAND TRIMER-CONTAINING ANTIGEN BINDING MOLECULES | September 2020 | January 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17040464 | EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF | September 2020 | August 2024 | Abandon | 47 | 1 | 0 | No | No |
| 16981278 | ANTI-GUCY2C CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS | September 2020 | July 2024 | Abandon | 46 | 1 | 0 | No | No |
| 16979929 | ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION | September 2020 | June 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 16979930 | ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION | September 2020 | July 2023 | Allow | 34 | 1 | 0 | Yes | No |
| 16980074 | ANTIBODY SPECIFICALLY BINDING TO FOLR1 AND USES THEREOF | September 2020 | August 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16979932 | ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION | September 2020 | August 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16979933 | ANTI-CD25 ANTIBODY AGENTS | September 2020 | October 2023 | Allow | 37 | 1 | 0 | Yes | No |
| 16979931 | ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION | September 2020 | August 2023 | Allow | 35 | 1 | 0 | No | No |
| 16979754 | IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY EGFR ANTIBODY | September 2020 | February 2024 | Abandon | 41 | 2 | 1 | No | No |
| 16979627 | USE OF ANTI-HUMAN SIRPA V1 ANTIBODIES AND METHOD FOR PRODUCING ANTI-SIRPA V1 ANTIBODIES | September 2020 | September 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 17011321 | ERYTHROCYTE-BINDING THERAPEUTICS | September 2020 | May 2024 | Allow | 44 | 3 | 0 | No | No |
| 16939154 | USE OF BMMFI REP PROTEIN AS BIOMARKER FOR COLORECTAL CANCER | July 2020 | December 2024 | Allow | 53 | 2 | 0 | No | No |
| 16964892 | HUMANIZED AND DE-IMMUNIZED ANTIBODIES | July 2020 | March 2024 | Allow | 44 | 1 | 0 | Yes | No |
| 16964517 | IMPROVED HINGE AREA AND USE OF SAME IN CONSTRUCTING CAR SKELETON | July 2020 | September 2024 | Allow | 50 | 2 | 0 | No | No |
| 16958615 | Antigen-Binding Proteins Targeting Shared Antigens | June 2020 | November 2025 | Abandon | 60 | 1 | 1 | No | No |
| 16955436 | NEOANTIGENS AND USES THEREOF | June 2020 | June 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16765830 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | May 2020 | September 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16764796 | METHODS FOR SELECTIVE EXPANSION OF DELTA-3 GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF | May 2020 | September 2024 | Allow | 52 | 1 | 1 | No | No |
| 16760240 | PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF ENGINEERED CELLS | April 2020 | October 2024 | Allow | 54 | 4 | 1 | Yes | No |
| 16758930 | ANTI-BAG2 ANTIBODY AND METHODS OF TREATING CANCER | April 2020 | July 2024 | Allow | 50 | 2 | 1 | No | No |
| 16756057 | TREATMENT OF CD20-POSITIVE B-CELL LYMPHOMA WITH OBINUTUZUMAB | April 2020 | June 2024 | Allow | 50 | 5 | 0 | Yes | No |
| 16649039 | DOSAGE REGIMEN FOR COMBINATION THERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT | March 2020 | September 2024 | Abandon | 54 | 4 | 0 | No | Yes |
| 16648568 | COMPOSITIONS AND METHODS FOR TREATING DIFFUSE LARGE B CELL LYMPHOMA | March 2020 | December 2024 | Abandon | 57 | 4 | 0 | No | Yes |
| 16623504 | ANTI-SULFATED GLYCOSAMINOGLYCAN ANTIBODY | March 2020 | March 2024 | Abandon | 51 | 2 | 1 | No | No |
| 16645092 | METHODS FOR IMPROVING ADOPTIVE CELL THERAPY | March 2020 | March 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16637909 | ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES THEREOF | February 2020 | June 2025 | Allow | 60 | 2 | 0 | No | No |
| 16635205 | ACTIVATION OF RESIDENT MEMORY T CELLS FOR THE TREATMENT OF CANCER | January 2020 | March 2025 | Allow | 60 | 6 | 1 | No | No |
| 16619500 | MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME | December 2019 | November 2023 | Allow | 48 | 2 | 1 | No | No |
| 16610433 | MESOTHELIN-TARGETED TRAIL TRIMER | November 2019 | November 2023 | Allow | 48 | 3 | 1 | No | No |
| 16460792 | DOSING REGIMENS AND DOSAGE FORMS FOR TARGETED TGF-B INHIBITION | July 2019 | January 2024 | Abandon | 55 | 3 | 1 | Yes | No |
| 16463062 | Anti-SIRP-Alpha Antibodies and Methods of Use Thereof | May 2019 | May 2023 | Allow | 48 | 3 | 1 | Yes | No |
| 16399052 | FLT3-BINDING CHIMERIC ANTIGEN RECEPTORS, CELLS, AND USES THEREOF | April 2019 | July 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16346393 | ANTI-BCMA CAR T CELL COMPOSITIONS | April 2019 | July 2024 | Allow | 60 | 4 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner EDGINGTONGIORDANO, FRANCESCA.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner EDGINGTONGIORDANO, FRANCESCA works in Art Unit 1643 and has examined 73 patent applications in our dataset. With an allowance rate of 72.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 48 months.
Examiner EDGINGTONGIORDANO, FRANCESCA's allowance rate of 72.6% places them in the 36% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by EDGINGTONGIORDANO, FRANCESCA receive 2.21 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by EDGINGTONGIORDANO, FRANCESCA is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +35.2% benefit to allowance rate for applications examined by EDGINGTONGIORDANO, FRANCESCA. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.3% of applications are subsequently allowed. This success rate is in the 47% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 75.0% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.